Article: Confirmed clinical benefit of BRAF and MEK co-inhibition in BRAF-mutant metastatic melanoma: updated data from coBRIM and BRIM7

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer